Saverio Cinieri
Overview
Explore the profile of Saverio Cinieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
185
Citations
1915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Berardi R, Parisi A, Maruzzo M, Bellani M, Beretta G, Boldrini M, et al.
Support Care Cancer
. 2024 Sep;
32(9):613.
PMID: 39222131
Aim: To identify barriers between health and communication in oncology in order to promote the best possible practice. The areas of communication to be focused on are communication directly with...
12.
Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, et al.
Cancer Treat Rev
. 2024 Aug;
130:102815.
PMID: 39208751
The introduction of PARP inhibitors has revolutionized the management and treatment of patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer. The implementation of PARP inhibitors in...
13.
Iacovino M, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, et al.
Lancet Reg Health Eur
. 2024 Jul;
42:100973.
PMID: 39036543
[This corrects the article DOI: 10.1016/j.lanepe.2024.100912.].
14.
Iacovino M, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, et al.
Lancet Reg Health Eur
. 2024 May;
42:100940.
PMID: 38813536
[This corrects the article DOI: 10.1016/j.lanepe.2024.100912.].
15.
Bonanni P, Maio M, Beretta G, Icardi G, Rossi A, Cinieri S
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675802
Patients with cancer can be immunocompromised because of their disease and/or due to anticancer therapy. In this population, severe influenza virus infections are associated with an elevated risk of morbidity...
16.
Iacovino M, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, et al.
Lancet Reg Health Eur
. 2024 Apr;
41:100912.
PMID: 38665620
Background: Generalizability of registrative clinical trials to real-world clinical practice is influenced by comparability of patients in the two settings. We compared characteristics of cancer patients in registrative trials with...
17.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti M, et al.
Breast
. 2024 Apr;
75:103725.
PMID: 38615483
Background: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II...
18.
Valsecchi A, Fusco V, Di Maio M, Santini D, Tucci M, De Giorgi U, et al.
Tumori
. 2024 Mar;
110(3):174-185.
PMID: 38462772
Purpose: Cancer treatment-induced bone loss is a side effect of hormonal therapy that can severely affect patients' quality of life. The aim of this survey was to obtain an updated...
19.
Fusco V, Di Maio M, Valsecchi A, Santini D, Tucci M, De Giorgi U, et al.
Support Care Cancer
. 2024 Mar;
32(3):202.
PMID: 38427111
Purpose: Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy;...
20.
Speranza D, Sapuppo E, Aprile G, Auriemma A, Bergamo F, Bianco R, et al.
Tumori
. 2024 Feb;
110(3):203-208.
PMID: 38326240
Introduction: About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the...